IL210922A0 - Treatment of pulmonary arterial hypertension - Google Patents

Treatment of pulmonary arterial hypertension

Info

Publication number
IL210922A0
IL210922A0 IL210922A IL21092211A IL210922A0 IL 210922 A0 IL210922 A0 IL 210922A0 IL 210922 A IL210922 A IL 210922A IL 21092211 A IL21092211 A IL 21092211A IL 210922 A0 IL210922 A0 IL 210922A0
Authority
IL
Israel
Prior art keywords
treatment
arterial hypertension
pulmonary arterial
pulmonary
hypertension
Prior art date
Application number
IL210922A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41137217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL210922(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL210922A0 publication Critical patent/IL210922A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL210922A 2008-08-13 2011-01-27 Treatment of pulmonary arterial hypertension IL210922A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8838208P 2008-08-13 2008-08-13
US16450109P 2009-03-30 2009-03-30
PCT/US2009/053358 WO2010019540A1 (en) 2008-08-13 2009-08-11 Treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
IL210922A0 true IL210922A0 (en) 2011-04-28

Family

ID=41137217

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210922A IL210922A0 (en) 2008-08-13 2011-01-27 Treatment of pulmonary arterial hypertension

Country Status (16)

Country Link
US (1) US20110190313A1 (enExample)
EP (1) EP2315592A1 (enExample)
JP (1) JP2011530607A (enExample)
KR (1) KR20110053354A (enExample)
CN (1) CN102123711A (enExample)
AU (1) AU2009282104A1 (enExample)
BR (1) BRPI0917491A2 (enExample)
CA (1) CA2732789A1 (enExample)
CL (1) CL2011000295A1 (enExample)
IL (1) IL210922A0 (enExample)
MA (1) MA32617B1 (enExample)
MX (1) MX2011001668A (enExample)
NZ (1) NZ590839A (enExample)
RU (1) RU2011109078A (enExample)
TW (1) TW201010999A (enExample)
WO (1) WO2010019540A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3130908A1 (en) 2009-06-30 2010-12-30 Mallinckrodt Hospital Products IP Limited Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
CN109568319A (zh) 2013-01-10 2019-04-05 普尔莫凯恩股份有限公司 非选择性激酶抑制剂
JP6799201B2 (ja) * 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
WO2015054574A1 (en) 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations
CN110087653A (zh) 2016-10-27 2019-08-02 普尔莫凯恩股份有限公司 用于治疗肺高血压的组合疗法
AU2017356955B2 (en) 2016-11-08 2023-11-09 Reata Pharmaceuticals Holdings, LLC Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
US20210038510A1 (en) * 2018-02-08 2021-02-11 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
WO2020232238A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Inhalable formulations for kinase inhibition
WO2021108303A1 (en) * 2019-11-25 2021-06-03 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
MX2022007044A (es) 2019-12-13 2022-06-24 Nippon Shinyaku Co Ltd Compuesto y composicion como inhibidor de cinasa del receptor de los factores de crecimiento derivados de las plaquetas (pdgf).
CN116568299A (zh) * 2020-09-11 2023-08-08 普尔莫西姆治疗有限责任公司 用于治疗或预防肺动脉高压的组合物和方法
IL302994A (en) 2020-11-17 2023-07-01 United Therapeutics Corp Inhaled imatinib for pulmonary hypertension field

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2004037261A1 (en) * 2002-10-25 2004-05-06 The Administrators Of The Tulane Educational Fund Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
BRPI0606872A2 (pt) * 2005-01-28 2009-07-21 Novartis Ag uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação de atividade de tie-2 quinase
RU2415672C2 (ru) * 2005-05-02 2011-04-10 Новартис Аг Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии
WO2007065898A1 (en) * 2005-12-06 2007-06-14 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
AU2007317349B2 (en) * 2006-11-03 2011-10-20 Irm Llc Compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
MA32617B1 (fr) 2011-09-01
RU2011109078A (ru) 2012-09-20
CA2732789A1 (en) 2010-02-18
BRPI0917491A2 (pt) 2015-12-01
WO2010019540A1 (en) 2010-02-18
TW201010999A (en) 2010-03-16
EP2315592A1 (en) 2011-05-04
MX2011001668A (es) 2011-03-25
CN102123711A (zh) 2011-07-13
NZ590839A (en) 2013-02-22
KR20110053354A (ko) 2011-05-20
JP2011530607A (ja) 2011-12-22
US20110190313A1 (en) 2011-08-04
AU2009282104A1 (en) 2010-02-18
CL2011000295A1 (es) 2011-07-15

Similar Documents

Publication Publication Date Title
ZA201006648B (en) Methods of treatment
IL216875A0 (en) Determination of coronary artery disease risk
BRPI0917491A2 (pt) tratamento de hipertensao arterial pulmonar
GB0818074D0 (en) Treatment of biofilms
IL212119A0 (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
IL207397A0 (en) Difluorobiphenylamide derivtives for the treatment of ocular hypertension
LT2504003T (lt) Nitroksilo donorai, skirti plaučių hipertenzijos gydymui
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
PL2365804T3 (pl) Zmniejszanie obciążenia amyloidem-beta w tkance niemózgowej
PL2056858T3 (pl) Leczenie stanów chorobowych płuc
IL208236A0 (en) Use of cathepsin c
ZA201307905B (en) Use of fk506 for the treatment of pulmonary arterial hypertension
IL209819A0 (en) Novel heterocyclyl compounds for treatment of cardiovascular disease
SI2491005T1 (sl) Uporaba 4-(etil(dimetil)amonio)butanoata pri zdravljenju bolezni srca in oĺ˝ilja
PL2145547T3 (pl) Zwiększona trwałość związków smakowo-zapachowych
EP2164494A4 (en) Methods of Treatment
IL212457A0 (en) Use of helium-oxygen gas mixtures for treating pulmonary arterial hypertension
GB0806047D0 (en) Treatment of heart failure
GB0723100D0 (en) Treatment of HFnEF
ZA201100559B (en) Treatment of pulmonary arterial hypertension
ATE533351T1 (de) Sieb
HK1155651A (en) Treatment of pulmonary arterial hypertension
EP2349299A4 (en) COMPOSITION FOR THE TREATMENT OF HYPERTENSION
GB0716840D0 (en) Treatment of cardiovascular disease
GB0817859D0 (en) Treatment of proteostatic disease